• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Effects of thrombolytic agents on pulmonary and venous clots in severe pulmonary embolism (author's transl)].

作者信息

Serradimigni A, Arnoux F, Franck R, Chiche G, Domani A, Juhan-Vague U

出版信息

Nouv Presse Med. 1981 Apr 4;10(15):1189-92.

PMID:7220291
Abstract

Thirty-eight patients admitted to hospital for pulmonary embolism of recent onset were divides into four treatment groups. Group I patients (10) received streptokinase in does of 250,000 units over 20 minutes, followed by 100,000 units/hour for a total of 24 hours. Group II patients (8) received urinary urokinase 4,500 CTA units/kg/hour during 12 hours. Group III patients (10) were treated with urinary urokinase (112,500 CTA) units/hour during 24 hours) and heparin (500 units/kg/24 hours). Group IV patients (10) were given tissue urokinase and heparin, both in the same dosage as in group III patients. Pulmonary angiography and cavography were performed in all patients before treatment and within 24 hours of its termination. With regard to pulmonary emboli, improvement was most pronounced with streptokinase, with a gain of 15.7 points on Miller's index of severity, as against 9.6, 10.5 and 5.7 points for Group II, III and IV patients respectively. In peripheral venous thrombosis, streptokinase showed even greater superiority over other treatment, with a gain of 16 points of Marder's index, as against zero, 4.5 and 11.2 points for patients in Groups II, III and IV respectively. On biochemical tests, the decrease in fibrinaemia was more pronounced in Group I patients than in other groups.

摘要

相似文献

1
[Effects of thrombolytic agents on pulmonary and venous clots in severe pulmonary embolism (author's transl)].
Nouv Presse Med. 1981 Apr 4;10(15):1189-92.
2
Thrombolytic treatment of acute pulmonary embolism.急性肺栓塞的溶栓治疗
Herz. 1989 Jun;14(3):157-71.
3
[Actual state of thrombolytic treatment of recent vein thrombosis and pulmonary embolism (author's transl)].
J Mal Vasc. 1981;6(4):251-6.
4
Treatment of pulmonary embolism and deep vein thrombosis with thrombolytic therapy.用溶栓疗法治疗肺栓塞和深静脉血栓形成。
Clin Chest Med. 1984 Sep;5(3):487-94.
5
[Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. Apropos of 67 cases].
Arch Mal Coeur Vaiss. 1986 Apr;79(4):435-42.
6
[Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism].[两种尿激酶方案治疗严重肺栓塞的多中心研究。尿激酶与肺栓塞研究组]
Arch Mal Coeur Vaiss. 1984 Jul;77(7):773-81.
7
[Efficacy and safety of thrombolytic therapy in the elderly with severe pulmonary embolism].[溶栓治疗在老年重度肺栓塞患者中的疗效与安全性]
Arch Mal Coeur Vaiss. 1995 Jun;88(6):825-31.
8
Therapeutic use of thrombolytic agents.溶栓剂的治疗用途。
Am J Hosp Pharm. 1981 Jun;38(6):817-24.
9
Clinical use of thrombolytic agents in venous thromboembolism.溶栓药物在静脉血栓栓塞症中的临床应用。
Arch Intern Med. 1982 Apr;142(4):684-8.
10
[Fibrinolytic treatment of deep venous thromboses with streptokinase at an ultrahigh dosage].[用超高剂量链激酶对深部静脉血栓进行纤溶治疗]
Dtsch Med Wochenschr. 1987 Apr 24;112(17):668-74. doi: 10.1055/s-2008-1068118.